Ewes bearing more than 1 fetus are more susceptible to pregnancy toxemia than those with a single fetus. Crossbreeding programs in Israel increased the occurrences of ewes bearing more than 2 fetuses; therefore, the aim was to assess the exacerbation in the metabolic status of ewes pregnant with several fetuses. Fifty ewes, genetically developed to achieve multiple-fetus pregnancies, were monitored, on average, from d 115 of pregnancy until lambing for plasma concentrations of several key metabolites and insulin. The numbers of fetuses were examined by ultrasonography at 35 d of pregnancy. Blood samples were collected weekly, and concentrations of glucose, β-hydroxybutyrate (BHBA), NEFA, triglycerides, cholesterol, total calcium, and insulin were determined. The average litter size was 2.75 (±1.1), and 1 (1F), 2 (2F), 3 (3F), and 4 or more (4F) fetuses were conceived, respectively, by 6 (12%), 17 (34%), 14 (28%), and 13 (26%) ewes. Total birth weights of lambs were 6.1, 9.5, 12.7, and 15.0 kg for 1F, 2F, 3F, and 4F, respectively (P < 0.001). Plasma glucose concentrations in 1F were greater than those in 3F and 4F (P < 0.05) and were similar among 2F, 3F, and 4F. Trends toward increasing plasma concentrations of BHBA and NEFA were observed as the number of fetuses increased and also as lambing approached. Plasma concentrations of BHBA and NEFA were, respectively, 3.7 (P< 0.002) and 2.1 (P < 0.001) times as great in 4F ewes as in 1F ewes. Trends toward decreased concentrations of triglycerides and cholesterol were observed as litter size increased. Insulin concentrations in blood decreased considerably as the numbers of fetuses increased and, on average, they were less by a factor of 5 in the 4F ewes than in the 1F ewes (P < 0.001). Moreover, insulin concentrations during the week before lambing were extremely low (e.g., 0.54 µIU/mL in the 4F ewes). Insulin concentrations were reduced in ewes bearing >3 fetuses, even 5 wk before lambing; this decline apparently began earlier than the last month of gestation. Therefore, it seems that insulin has a pivotal role in the etiology of pregnancy ketonemia in ewes carrying multiple fetuses. The present findings may suggest that the decline in insulin concentrations that apparently occurs in the earlier stages of pregnancy represents a homeorhetic control to spare glucose for the brains and fetoplacental units of the dams. The results clearly demonstrate the increased susceptibility to pregnancy toxemia of ewes carrying multiple fetuses. Appropriate nutritional strategies should be developed for ewes that conceive >3 fetuses, to meet the increased nutritional requirements of the fetoplacental unit.
The present study was conducted in an Assaf flock in which the FecB (Booroola) mutation was segregated to determine whether the FecB mutation affects birthweight and the pre- and post-weaning growth rate of ewe lambs, as well as the mature bodyweight of ewes. Significant differences (P = 0.01) in birthweight (mean +/- s.e.m.) were found between BB ewe lambs (4.03 +/- 0.08 kg) and B+ and ++ ewe lambs (4.16 +/- 0.04 and 4.32 +/- 0.07 kg, respectively), which themselves did not differ significantly (P > 0.05). An FecB-associated maternal effect on the birthweight of ewe lambs was also detected, with the birthweight of lambs born to BB mothers (3.93 +/- 0.08 kg) being significantly (P < 0.0001) different from the birthweight of lambs born to B+ and ++ mothers (4.26 +/- 0.04 and 4.33 +/- 0.07 kg, respectively), which did not differ significantly. The genotypes of the lambs did not affect their preweaning growth rate. However, the post-weaning growth rate of ewe BB lambs (274 +/- 5 g day(-1)) was significantly (P = 0.05) different from the similar (P > 0.05) post-weaning growth rates of B+ and ++ lambs (284 +/- 3 and 290 +/- 4 g day(-1), respectively). The genotype at the FecB locus also affected the mature bodyweight of ewes, with that of BB ewes (67.3 +/- 1.4 kg) being significantly (P < 0.001) different from the similar mature bodyweight of B+ and ++ ewes (70.8 +/- 1.1 and 70.1 +/- 1.7 kg, respectively).
PREGNANCY toxaemia in sheep is a metabolic disorder associated with carrying multiple fetuses (Sargison 2007). It is characterised by hypoglycaemia and hyperketonaemia due to the inability of the ewe to maintain an adequate energy balance in late pregnancy. Common treatments for ewes affected with pregnancy toxaemia include the oral administration of glycerol or propylene glycol solutions, intravenous glucose, and, at more than 135 days of gestation, injection of dexamethasone or beta methasone to induce parturition (Radostits and others 2007), with the aim of eliminating the metabolic demand for energy of the gravid uterus.Breeding for high prolificacy by the introgression of the Booroola mutation has led to the creation of the highly prolific Afec-Assaf strain of sheep (Gootwine and others 2008). The average prolificacy of AfecAssaf ewes is 2·55 lambs born per lambing, with approximately 44 per cent of litters containing three or four lambs.Afec-Assaf ewes are kept in an experimental flock at the Volcani Center, Bet Dagan, Israel, under intensive management conditions, indoors all year round. Reproductive management of the flock includes three to four lambing periods in a year, following oestrus synchronisation, hand-mating and ultrasonographic pregnancy diagnosis at approximately 35 days after mating. The specificity and sensitivity of pregnancy diagnosis for ewes lambing fewer than three lambs (n=388) are 0·93 and 0·89, respectively; in ewes lambing three or more lambs (n=105) the specificity is 0·66 and the sensitivity 0·76 (E. Gootwine, unpublished data). Based on the pregnancy diagnosis results, pregnant ewes are divided into two groups: sheep carrying fewer than three fetuses and sheep carrying three or more fetuses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.